[
  {
    "ts": null,
    "headline": "Abbott (ABT): Assessing Valuation After New Regulatory Wins for Its Pediatric Heart Device Innovation",
    "summary": "Abbott Laboratories (ABT) just picked up fresh FDA clearance and a CE Mark for its Amplatzer Piccolo Delivery System, a pediatric heart device upgrade that could quietly strengthen both its structural heart franchise and its long term growth story. See our latest analysis for Abbott Laboratories. These approvals land while Abbott’s 1 year total shareholder return of 15.35 percent and double digit year to date share price return signal steady, if not explosive, momentum, supported by board...",
    "url": "https://finnhub.io/api/news?id=f99a66c4c772639975beb4d60793e083e8a6e0534756c3a1c424033155aa13ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766074643,
      "headline": "Abbott (ABT): Assessing Valuation After New Regulatory Wins for Its Pediatric Heart Device Innovation",
      "id": 137825329,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (ABT) just picked up fresh FDA clearance and a CE Mark for its Amplatzer Piccolo Delivery System, a pediatric heart device upgrade that could quietly strengthen both its structural heart franchise and its long term growth story. See our latest analysis for Abbott Laboratories. These approvals land while Abbott’s 1 year total shareholder return of 15.35 percent and double digit year to date share price return signal steady, if not explosive, momentum, supported by board...",
      "url": "https://finnhub.io/api/news?id=f99a66c4c772639975beb4d60793e083e8a6e0534756c3a1c424033155aa13ff"
    }
  },
  {
    "ts": null,
    "headline": "What Abbott Laboratories (ABT)'s New Pediatric Heart Device Clearances Mean For Shareholders",
    "summary": "Abbott Laboratories recently received U.S. FDA clearance and CE Mark for its Amplatzer Piccolo Delivery System, enabling more precise, minimally invasive closure of patent ductus arteriosus in premature infants using Abbott’s pea‑sized Amplatzer Piccolo Occluder. This advancement deepens Abbott’s presence in pediatric cardiology by expanding its portfolio of specialized devices for critically ill newborns, potentially strengthening hospital adoption of its broader structural heart...",
    "url": "https://finnhub.io/api/news?id=283689df36837d01073564e28b33188c4f290cafa3a7864c5b1b2ae961d458d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766072388,
      "headline": "What Abbott Laboratories (ABT)'s New Pediatric Heart Device Clearances Mean For Shareholders",
      "id": 137825330,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories recently received U.S. FDA clearance and CE Mark for its Amplatzer Piccolo Delivery System, enabling more precise, minimally invasive closure of patent ductus arteriosus in premature infants using Abbott’s pea‑sized Amplatzer Piccolo Occluder. This advancement deepens Abbott’s presence in pediatric cardiology by expanding its portfolio of specialized devices for critically ill newborns, potentially strengthening hospital adoption of its broader structural heart...",
      "url": "https://finnhub.io/api/news?id=283689df36837d01073564e28b33188c4f290cafa3a7864c5b1b2ae961d458d6"
    }
  },
  {
    "ts": null,
    "headline": "Can Abbott Laboratories (ABT) Deliver Resilient Returns in the Long Term?",
    "summary": "Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund focuses on owning a concentrated portfolio of U.S. large-cap stocks. For the third quarter of 2025, the fund reported a net return of 7.46% outperforming its benchmark, the […]",
    "url": "https://finnhub.io/api/news?id=4af145b700c89a8c705d368b8cde002b20c1984f3d1206c3a7ba143f4bf90a40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766068060,
      "headline": "Can Abbott Laboratories (ABT) Deliver Resilient Returns in the Long Term?",
      "id": 137821708,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund focuses on owning a concentrated portfolio of U.S. large-cap stocks. For the third quarter of 2025, the fund reported a net return of 7.46% outperforming its benchmark, the […]",
      "url": "https://finnhub.io/api/news?id=4af145b700c89a8c705d368b8cde002b20c1984f3d1206c3a7ba143f4bf90a40"
    }
  },
  {
    "ts": null,
    "headline": "Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart",
    "summary": "Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer Piccolo™ Delivery System, which is used with the company's Amplatzer Piccolo Occluder. The new delivery system is designed specifically to treat premature babies (some weighing as little as two pounds) with a hole in the heart known as a patent ductus arteriosus (PDA).",
    "url": "https://finnhub.io/api/news?id=9da7787c5b45e671abaa86796131037c6812cdf83df3b0e73981e0f35ce5d5d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766066400,
      "headline": "Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart",
      "id": 137821709,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer Piccolo™ Delivery System, which is used with the company's Amplatzer Piccolo Occluder. The new delivery system is designed specifically to treat premature babies (some weighing as little as two pounds) with a hole in the heart known as a patent ductus arteriosus (PDA).",
      "url": "https://finnhub.io/api/news?id=9da7787c5b45e671abaa86796131037c6812cdf83df3b0e73981e0f35ce5d5d7"
    }
  },
  {
    "ts": null,
    "headline": "2 Dividend Stocks to Buy for 2026 and Beyond",
    "summary": "The healthcare sector is a great place to find quality income stocks, and these two appear to be strong picks.",
    "url": "https://finnhub.io/api/news?id=5b6aa7756761eb5f2382bcd7929610e249d9e34802b5bc0b76d664000ed51759",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766061120,
      "headline": "2 Dividend Stocks to Buy for 2026 and Beyond",
      "id": 137821710,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The healthcare sector is a great place to find quality income stocks, and these two appear to be strong picks.",
      "url": "https://finnhub.io/api/news?id=5b6aa7756761eb5f2382bcd7929610e249d9e34802b5bc0b76d664000ed51759"
    }
  }
]